Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

  • Ten Years of Tamoxifen Reduces Breast Cancer Recurrences, Improves Survival
    (Posted: 03/20/2013) - Taking adjuvant tamoxifen for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.
  • Video Eases End-of-Life Care Discussions
    (Posted: 01/12/2010, Updated: 01/03/2013) - Patients with advanced cancer who watched a video that depicts options for end-of-life care were more certain of their end-of-life decision making than patients who only listened to a verbal narrative and were likely to choose comfort care over aggressive medical care for their end-of-life care preferences, according to an article published online November 30, 2009, in the Journal of Clinical Oncology.
  • Abiraterone Improves Survival in Metastatic Prostate Cancer
    (Posted: 07/27/2011, Updated: 12/31/2012) - A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.
  • New Drug Shows Promise against Drug-Resistant Leukemias
    (Posted: 12/17/2012) - A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.
  • New Targeted Treatment May Slow Disease in Patients with Advanced GIST
    (Posted: 12/11/2012) - A new oral drug, regorafenib (Stivarga®), may delay the progression of advanced gastrointestinal stromal tumors (GIST) that are resistant to treatment, according to results from an international clinical trial published November 22, 2012, in The Lancet.
< Previous  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  Next >